Anti-CD20 monoclonal antibody

This page covers all Anti-CD20 monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20.

Targets

CD20

Marketed (1)

• Kesimpta · Novartis · Immunology
  Ofatumumab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.

Phase 3 pipeline (1)

• Obinutuzumab administration · Radboud University Medical Center · Oncology
  Obinutuzumab is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct cell death.